Shire PLC is a specialty biopharmaceutical company. They have a global sales and marketing infrastructure with a broad portfolio of products and direct marketing capability in the US, Canada, UK, Republic of Ireland, France, Germany, Italy and Spain.

At Shire, we enable people with life altering conditions to lead better lives. We focus on developing and delivering innovative treatments for patients with rare diseases and other specialty conditions. 

To realize our aspiration to become a leading global biotech, our efforts are concentrated on four key strategic drivers: growth, innovation, efficiency, and people. Our priorities are to drive optimal performance of our existing products, increase patient access to these medicines, and to build our pipeline through research and development and partnerships in order to deliver new medicines to patients.
Company Growth (employees)
Jersey, JE
Size (employees)
23,906 (est)
Shire was founded in 1986 and is headquartered in Jersey, JE

Key People/Management at Shire

Graham Hetherington

Graham Hetherington

Chief Financial Officer
William Burns

William Burns

Non-Executive Director
Susan Kilsby

Susan Kilsby

Non-Executive Director
Steven Gillis

Steven Gillis

Non-Executive Director
David Kappler

David Kappler

Deputy Chairman

Shire Office Locations

Shire has offices in Jersey, Dublin, Lexington, Zug and in 37 other locations
Jersey, JE (HQ)
No. 99854, 22 Grenville Street, St Helier
São Paulo, BR
Av. das Nações Unidas, 14.171, 5o andar
Saint-Laurent, CA
2250 Alfred-Nobel Blvd, Suite 500
Dublin, IE
5 Riverwalk
Zug, CH
Zählerweg 10
Lexington, US
300 Shire Way
Show all (41)

Shire Financials and Metrics

Shire Financials

Shire's revenue was reported to be £47.6 m in FY, 2016

Revenue (Q1, 2017)

3.6 b

Gross profit (Q1, 2017)

2.2 b

Gross profit margin (Q1, 2017), %


Net income (Q1, 2017)

375 m

Market capitalization (27-Oct-2017)

42.4 b

Closing share price (27-Oct-2017)


Cash (31-Mar-2017)

369 m
Shire's current market capitalization is $42.4 b.
GBPFY, 2006FY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016


108 m98.3 m114 m111.4 m103.4 m109.3 m120.6 m122.3 m67.1 m58.2 m47.6 m

Revenue growth, %


Operating expense total

159.8 m95.1 m100.7 m104.7 m106.5 m113.1 m120.3 m123.2 m70.1 m55.9 m46.4 m


32.9 m40.9 m34.4 m(1.1 m)(1.5 m)3 m1.7 m(433 k)3.7 m1.8 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017


1.6 b1.7 b1.7 b2.4 b3.5 b3.6 b

Cost of goods sold

228 m262.7 m248.6 m778.1 m1.7 b1.3 b

Gross profit

1.3 b1.4 b1.5 b1.7 b1.7 b2.2 b

Gross profit Margin, %

GBPFY, 2006FY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016


4 k528.8 m

Accounts Receivable

2.6 b


455.3 m544.8 m635.4 m3.6 b

Current Assets

51.1 m75.3 m116.7 m143.6 m148.2 m145.6 m148.6 m156.6 m151.6 m158.9 m7.5 b
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017


153.6 m467.7 m74.3 m64 m44.9 m69 m693.4 m728.6 m369 m

Accounts Receivable

1.1 b1.1 b1.1 b1.1 b1.3 b1.3 b2.4 b2.6 b2.6 b


585 m548.9 m588.7 m632.8 m608.9 m680 m5.8 b4.9 b3.3 b

Current Assets

2.6 b2.9 b2.5 b2.5 b2.7 b2.4 b9.7 b8.9 b7.1 b
    GBPFY, 2006FY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016

    Net Income

    (65.5 m)7.5 m15.1 m4.7 m(1.9 m)(2.7 m)1.6 m1.6 m(2.9 m)2.9 m327.4 m

    Depreciation and Amortization

    324.4 m407.3 m637.2 m1.5 b

    Accounts Receivable

    (210 m)(701.7 m)

    Cash From Operating Activities

    2.7 b
    USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

    Net Income

    753.5 m1.2 b410.4 m570 m1 b419 m375 m

    Depreciation and Amortization

    204.8 m307.1 m120.6 m291.8 m457.4 m168.9 m429.8 m877.8 m486.9 m

    Accounts Receivable

    (37.3 m)(92.1 m)(85.1 m)(84.9 m)(288.1 m)(100.9 m)(181 m)(411.2 m)(35.3 m)

    Cash From Operating Activities

    1.1 b1.7 b561.6 m1 b1.6 b389.5 m980.4 m1.5 b459.1 m
      USDY, 2017


      149.4 k

      Financial Leverage

      2.2 x
      Show all financial metrics

      Shire Operating Metrics

      FY, 2014FY, 2015FY, 2016



      Projects in R&D Pipeline


      Phase II Trials


      Phase III Trials

      Show all operating metrics

      Shire Market Value History

      Shire Revenue Breakdown

      Shire's employees are reported to be approximately 52% female and 48% male.

      Shire Median Salaries

      Source: 25 public H-1B filings from Shire
      Show all human capital metrics

      Shire's Web-traffic and Trends

      Shire Online and Social Media Presence

      Shire News and Updates

      Under breakup pressure, Shire cheers grumpy investors with Q3 earnings beat

      Shire shares have taken a beating this year, but they got a boost Friday from third-quarter earnings results investors viewed favorably.

      IT Security: A hygiene factor or differentiator?

      Law firm IT security has never been as high on the client radar thanks to a growing awareness of the prevailing rise in cybercrime, GDPR, and yes, DLA Piper being hit by that not Petya virus. We speak to a number of high profile non-financial services GCs to find out what is on their agenda and whet…

      Activist hedge fund angles for Shire breakup to revive struggling shares

      Shire has hinted that a spinoff of its neuroscience unit may be in the works. But one U.S. hedge fund wants more.

      Shire, Pfizer antitrust lawsuits could rewrite the rules for formulary contracts: report

      Shire's antitrust lawsuit against Allergan is the latest in a string of federal cases that challenge pharma's long-standing negotiation practices with payers. The verdicts could change the ways drugmakers strike deals with payers, and may end up benefiting biosimilars and other follow-on products, o…

      Plasma Protein Therapeutics Market 2017 Global Manufactures : CSL Behring, China Biologics, Kedrion and Shire Plc.

      Market Research Store added a depth and professional market study report on Global Plasma Protein Therapeutics Market 2017. This report also provides more details about Market Size, Share, Analysis, import/export consumption, supply and demand Figures, cost, price, revenue and gross margins. Posted …

      FDA flags 19 deaths in Ocaliva patients, putting Intercept's NASH bid in doubt

      Intercept has been the presumed leader in a race toward one of the hottest new markets in pharma, the liver disease NASH. But 19 deaths in current Ocaliva patients pose a threat to those hopes, and the med faces a setback in its now-approved indication, too.
      Show more

      Shire Company Life and Culture

      You may also be interested in